ClinicalTrials.gg
CompletedNCT06642116ENHANCEUpdated Sep 17, 2026

Evaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate

An interventional study of OCEAN in Rhinosinusitis Chronic, Wound Healing and Sinus Surgery, sponsored by Polyganics BV. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Polyganics BV · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Rhinosinusitis with a site in United States — 11 open to participants now, 18 under way, 7 of them phase 3. Rhinosinusitis · United States.

Enrollment
49th of 55
10 · median 59
Started
2025
with 6 others
No phase
17 of 71
4 open now
Registered
58th of 71
by date

Among the 71 studies in Rhinosinusitis with a site in United States, this one is the 49th largest by enrollment of the 55 interventional ones that give a count, is one of 7 that started in 2025, is one of 17 with no phase, and was the 58th registered.

Rhinosinusitis

252 studies on the registry are indexed under Rhinosinusitis; 70 are open to participants now.

Browse Rhinosinusitis studies →

Open to participants now

11 of the 71 studies in Rhinosinusitis with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Rhinosinusitis studies recruiting now, 15 (44%) set no upper age limit and 13 (38%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Rhinosinusitis with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to investigate the safety and performance of OCEAN® as an adjunct in wound healing after nasal/sinus surgery by using OCEAN® in patients undergoing nasal/sinus surgery.

03

Conditions studied

  • Rhinosinusitis Chronic
  • Wound Healing
  • Sinus Surgery
  • Mometasone Furoate

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is 18 years or older
  2. Patient is scheduled to undergo bilateral endoscopic sinus surgery for Chronic Rhinosinusitis with nasal polyps (CRSwNP) or Chronic Rhinosinusitis without nasal polyps (CRSsNP)
  3. Patient is willing and able to comply with all study elements as indicated by their written
  4. Patients with a pre-operative Lund-MacKay score of ≥ 6.

Exclusion criteria

Exclusion Criteria:

  1. Patient is pregnant or nursing
  2. Patients with a history of chronic epistaxis or experienced a significant epistaxis event (defined as epistaxis requiring medical intervention) in the past 3 months
  3. Patients with a disorder
  4. Patients with a known or suspected allergy to device components
  5. Patients with known hemophilia
  6. Patients with insulin dependent diabetics
  7. Patients with an oral dependent condition
  8. Patients with glaucoma, ocular hypertension, posterior subcapsular cataracts
  9. Patients with a (previous) diagnosis of Samter's Triad (aspirin-exacerbated respiratory disease (AERD))
  10. Patients that require nasal ointments or creams at time of device placement
  11. Patients with a neurological, medical, psychiatric condition, or social circumstance that would potentially increase risk, interfere with study participation, or confound interpretation of study data
  12. Patients with plans to (or otherwise anticipate the need to) undergo an ear, nose, throat (ENT) procedure within the 90 day study follow up
  13. Patients participating in another clinical research study (within 30 days prior to screening up till 90 days post-operative).
  14. Patients that used any form of corticosteroid or immunologics within 2 weeks prior to sinus surgery or during follow-up to day 30.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    OCEAN

    Application of OCEAN after nasal/sinus surgery

    Device: OCEAN

Interventions

  • DeviceOCEAN

    Biodegradable nasal dressing

06

What researchers measure

Primary outcomes

  1. Rate of Serious Adverse Events

    Rate of serious adverse events related to the use of the OCEAN bioresorbable nasal dressing post nasal surgery

    Time frame: Up to 25 days after surgery

  2. Performance

    Endoscopic evaluation of aspects of wound healing as assessed using the Lund-Kennedy Endoscopic Score System (LKS). The LKS assesses various factors like edema, crusting, discharge, polyps, and mucosal inflammation. Each parameter is scored from 0 to 2, with 0 being normal and 2 representing severe findings. Higher scores on the Lund-Kennedy Scale indicate a worse outcome, reflecting more severe disease or poor wound healing. Minimum Value: 0 (This represents no signs of inflammation or disease); Maximum Value: 20 (This indicates the most severe signs of disease or inflammation)

    Time frame: Up to 25 days after surgery

07

Study locations

3 sites
  • Centers for Advanced ENT Care (CAdENT)
    Baltimore, Maryland 21204, United States
  • Ear Nose and Throat Consultants
    Detroit, Michigan 48034, United States
  • Ogden Clinic
    Ogden, Utah 84403, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Jun 2025, 4 months.

Of 33 interventional studies with no phase under Rhinosinusitis, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 36. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2024
First posted
Oct 15, 2024
StartActual
Feb 10, 2025
Primary completionActual
Jun 17, 2025
CompletionActual
Aug 25, 2025
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06642116
Lead sponsor
Polyganics BV
Collaborators
NAMSA
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Feb 10, 2025
Primary completion
Jun 17, 2025
Completion
Aug 25, 2025
Last update
Sep 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion